RxDoctor Payments Data

Bruce Decter, MD

Cardiovascular Disease · New Hyde Park, NYNPI 1114905437

Payments from drug & device makers

$88,888in general payments, 2019–2025

Across 1,099 payments — averaging $80.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$36K
  • Amarin Pharma, Inc.$26K
  • Sanofi-aventis U.S. LLC$7K
  • Regeneron Healthcare Solutions, Inc.$4K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$4,9506%
  • Speaking & faculty fees$57,68665%
  • Travel & lodging$3,7334%
  • Food & beverage$22,31725%
  • Education$2010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer157$35,503
Amarin Pharma, Inc.78$25,568
Sanofi-aventis U.S. LLC36$6,685
Regeneron Healthcare Solutions, Inc.28$4,490
AstraZeneca72$1,698
Johnson & Johnson55$1,664
Novartis107$1,512
E.r. Squibb & Sons, L.L.C.98$1,412
Boehringer Ingelheim42$1,258
Abbott37$1,172
Merck41$868
Amgen55$787
Edwards Lifesciences23$716
Alnylam Pharmaceuticals Inc.19$667
Kowa Pharmaceuticals America, Inc.25$411
Medicomp Inc6$340
Novo Nordisk25$321
Astellas Pharma US Inc8$287
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)12$286
Currax Pharmaceuticals LLC22$214
Arbor Pharmaceuticals, Inc.14$213
Biotronik Inc.5$205
Boston Scientific9$197
Esperion Therapeutics, Inc.8$166
Althera Pharmaceuticals LLC9$162
Kiniksa Pharmaceuticals, Ltd.9$143
Inspire Medical Systems, Inc.6$139
Vivaquant Inc, Dba Rhythm Express4$138
Actelion Pharmaceuticals US, Inc.8$122
Medtronic(2 entities)6$111
Lundbeck LLC7$110
Cvrx, Inc.4$102
Scpharmaceuticals Inc.4$93
Lilly USA, LLC4$88
Bridgebio Pharma, Inc.4$88
Azurity Pharmaceuticals, Inc.5$86
Nalpropion Pharmaceuticals LLC5$85
Bardy Diagnostics, Inc.5$81
GSK4$78
Kiniksa Pharmaceuticals International, PLC3$72
Heartflow, Inc.4$69
Daiichi Sankyo Inc.2$44
CSL Behring2$43
Lexicon Pharmaceuticals, Inc.2$39
Kestra Medical Technology Services, Inc.2$36
Tactile Systems Technology Inc2$32
Akcea Therapeutics, Inc.2$28
Impulse Dynamics (USA) Inc.1$27
Baxter Healthcare1$26
Philips North America LLC1$23
Ionis Pharmaceuticals, Inc.1$23
American Regent1$21
Eisai Inc.1$20
Bayer1$19
Amryt Pharma Holdings Ltd1$19
Irhythm Technologies, Inc.1$15
Gilead1$14
Medicure Pharma Inc.1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
AbbVie1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,888 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$1,383,361
Medicare patients
1,611
Services billed
14,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$117,364
XareltoRivaroxaban62$84,343
Repatha SureclickEvolocumab36$40,821
JardianceEmpagliflozin37$40,330
EntrestoSacubitril/Valsartan29$34,422
OzempicSemaglutide19$28,168
MultaqDronedarone Hcl19$25,088
FarxigaDapagliflozin Propanediol20$21,539
BrilintaTicagrelor26$21,132
Praluent PenAlirocumab19$18,468
EdarbyclorAzilsartan Med/Chlorthalidone24$13,134
EdarbiAzilsartan Medoxomil25$11,486
VascepaIcosapent Ethyl17$10,520
Icosapent Ethyl17$6,369
Nebivolol Hcl78$5,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35,503$117,364101 claims
Johnson & JohnsonXarelto$1,664$84,34362 claims
AstraZenecaFarxiga, Brilinta$1,698$42,67146 claims
Boehringer IngelheimJardiance$1,258$40,33037 claims
NovartisEntresto$1,512$34,42229 claims
Novo NordiskOzempic$321$28,16819 claims
Sanofi-aventis U.S. LLCMultaq$6,685$25,08819 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$213$24,62049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →